Search research articles
Contact Us
Filters
Showing results (221-230 of 248) with videos related to
Page
of 25
Sort By:
Plos One
|
September 19, 2014
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers
Laura W Goff, Nilay Thakkar, Liping Du, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2022
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
Aung Naing, John D Powderly, John J Nemunaitis, et al.
Oncology
|
June 24, 2019
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
David Hong, Drew Rasco, Michael Veeder, et al.
The Oncologist
|
June 9, 2017
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS
Christopher H Lieu, Manuel Hidalgo, Jordan D Berlin, et al.
British Journal of Cancer
|
December 12, 2018
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
Vera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
British Journal of Cancer
|
July 28, 2019
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
Vera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
Journal of Medicinal Chemistry
|
November 2, 1999
Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors
D Zacheis, A Dhar, S Lu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 1, 2021
First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-<sup>11</sup>C]-Glutamine in Patients with Metastatic Colorectal Cancer
Allison S Cohen, Joe Grudzinski, Gary T Smith, et al.
Annals of Surgical Oncology
|
February 26, 2013
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design
Matthew H G Katz, Robert Marsh, Joseph M Herman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 19, 2014
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes
Lee M Ellis, David S Bernstein, Emile E Voest, et al.
Page
of 25
Search research articles
Search
Showing results (221-230 of 248) with videos related to
Sort By:
Page
of 25
Plos One
|
September 19, 2014
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers
Laura W Goff, Nilay Thakkar, Liping Du, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2022
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
Aung Naing, John D Powderly, John J Nemunaitis, et al.
Oncology
|
June 24, 2019
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
David Hong, Drew Rasco, Michael Veeder, et al.
The Oncologist
|
June 9, 2017
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS
Christopher H Lieu, Manuel Hidalgo, Jordan D Berlin, et al.
British Journal of Cancer
|
December 12, 2018
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
Vera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
British Journal of Cancer
|
July 28, 2019
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
Vera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
Journal of Medicinal Chemistry
|
November 2, 1999
Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors
D Zacheis, A Dhar, S Lu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 1, 2021
First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-<sup>11</sup>C]-Glutamine in Patients with Metastatic Colorectal Cancer
Allison S Cohen, Joe Grudzinski, Gary T Smith, et al.
Annals of Surgical Oncology
|
February 26, 2013
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design
Matthew H G Katz, Robert Marsh, Joseph M Herman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 19, 2014
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes
Lee M Ellis, David S Bernstein, Emile E Voest, et al.
Page
of 25